MEITL, EATL Type II
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) (NCT04021082) | Portola Pharmaceuticals | 2019-11-15 |
Track MEITL, EATL Type II automatically
Every clearance here is in the API, with alerts when new ones post.